Tempus AI (NASDAQ:TEM) Cut to “Market Perform” at William Blair

William Blair downgraded shares of Tempus AI (NASDAQ:TEM) from an outperform rating to a market perform rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Wolfe Research started coverage on shares of Tempus AI in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. TD Cowen reiterated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Guggenheim assumed coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $73.88 on Wednesday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The business’s fifty day moving average price is $45.21 and its two-hundred day moving average price is $49.73. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $79.49.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Eric P. Lefkofsky sold 80,388 shares of Tempus AI stock in a transaction on Friday, February 7th. The stock was sold at an average price of $67.53, for a total transaction of $5,428,601.64. Following the sale, the chief executive officer now directly owns 5,293,005 shares of the company’s stock, valued at $357,436,627.65. This represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,229,449 shares of company stock valued at $102,293,124.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kovitz Investment Group Partners LLC bought a new position in Tempus AI during the 3rd quarter worth approximately $1,367,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tempus AI in the fourth quarter worth $1,091,000. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors acquired a new position in shares of Tempus AI in the 3rd quarter valued at $2,726,000. Finally, Sigma Planning Corp bought a new stake in shares of Tempus AI in the 3rd quarter valued at $1,323,000. 24.22% of the stock is currently owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.